Even more expertise at Onco-Innovations: Renowned Prof.

Steven Jones appointed Senior Scientific Advisor

 EQS Media / May 23, 2025 / 11:10 a.m. CET/CEST

Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco or the
Company, announces the appointment of Professor Steven Jones as Senior
Scientific Advisor. Professor Jones will play a key role in
Realizing the company's mission to improve cancer treatment
to revolutionize through AI-supported precision oncology.

Professor Jones is currently Co-Director of the Genome Sciences Centre in
Vancouver and Head of Bioinformatics and Distinguished Scientist at BC
Cancer Research Institute. He is internationally recognized as one of the most cited
researcher in his field and has made groundbreaking contributions to
Genomics and cancer research. His numerous awards include
include membership in the Royal Society of Canada and the Canadian
Academy of Health Sciences and several awards for his leadership in
of genomics and precision oncology. It is run by Clarivate Analytics
regularly cited as one of the world's most cited researchers.
https://www.bcgsc.ca/people/steven-jones

As a world-renowned expert in genomics, bioinformatics and
Cancer research brings Professor Jones his decades of experience in
Precision Oncology at Onco-Innovations. A significant part of his
extensive research program focuses on the development
more precise cancer treatments by using the specific genetic
profile of a patient’s cancer. In his new role,
he is the scientific director of the oncology genomics and AI initiatives
of the company and will mainly focus on the
subsidiary Inka Health. Inka Health has SynoGraph,
Onco-Innovations’ AI-powered flagship oncology platform,
and Professor Jones will lead the scientific direction of the
He will also shape the company’s research strategy
develop, maintain strategic partnerships and position the company in
represented in scientific and medical circles.

Professor Jones’ responsibilities include scientific management
Onco’s AI-powered solutions, promoting collaboration with
Research institutions and industrial partners as well as participation in
important publications and conferences. In addition, he will actively
take care of fundraising and public relations
and help investors and other stakeholders
scientific value and the importance of the technologies of
To convey onco-innovations.

Thomas OShaughnessy, CEO of Onco-Innovations, commented on the personnel
as follows:

"Professor Jones is a pioneer in the field of cancer genomics and
Bioinformatics, and we are delighted to welcome him to Onco-Innovations
His in-depth expertise and visionary leadership
will help us to further develop our activities in the field of
Precision Oncology and expand our collaboration with data partners,
clinicians and researchers worldwide."

About Inka Health

Inka Health is a company that uses AI-supported
Analysis methods for oncology research and drug development
revolutionized by advanced causal AI. The company's proprietary platform
SynoGraph uses AI-supported causal reasoning to determine which
cancer patients are most likely to respond to certain treatments, and causes
thus making progress in precision medicine. By integrating
various multimodal medical data from the fields of genomics,
Transcriptomics and proteomics, SynoGraph uncovers hidden insights,
both treatment decisions and clinical trial planning
With this cutting-edge technology, Inka Health aims to
Support pharmaceutical companies in developing medicines
to reduce study failures and provide life-saving
Bring therapies to market more quickly.

About Onco-Innovations Limited

Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) is a
Cancer research and treatment company in Canada with the
Focus on oncology. Onco-Innovations has set itself the task of
Prevention and treatment of cancer through pioneering
research and pursue innovative solutions. The company has
a worldwide exclusive license for a patented technology
which specifically targets solid tumors.

Oncology - an expanding billion-dollar market

Cancer is one of the most pressing medical challenges
of our time. Market dynamics impressively underline this importance:
By 2033, analysts forecast a global market volume of 521.60
billion USD, of which 180.12 billion USD in the United States alone
States. In Germany, around 500,000 people receive a
Cancer diagnosis - with a continuing upward trend. The economic
The impact is considerable: Worldwide, cancer causes
annual costs of USD 1.16 trillion. The IQVIA Institute for Human Data
Science expects a continuous increase in spending in oncology
by 2028, driven by groundbreaking innovations such as
Nanoparticle technologies as well as cell and gene therapies.

Breakthrough with PNKP inhibitor technology

Onco-Innovations has acquired an exclusive license for a
innovative technology strategically positioned: The new class of
PNKP inhibitors open up previously unknown therapeutic approaches for
the treatment of solid tumors and has the potential to replace established
to fundamentally change treatment standards.

Onco-Innovations subsidiary Inka Health continues successful collaboration!

Onco-Innovations subsidiary Inka Health Corp. has another
Agreement for analytical work signed with AstraZeneca Canada.
The new agreement is intended to be the next phase of real-world evidence
(RWE) research and its scientific dissemination.
This renewed contract signals a clear confidence in the
Inka Health’s capabilities, drug evaluation,
Submission strategies and evidence planning within the Canadian
regulatory framework. Under the new contract, Inka will
Health the development of a peer-reviewed scientific manuscript
that reflects the evolving role of international RWE in
Submissions to the Canadian Drug Agency (CDA) were examined.
Project includes an extended analysis and synthesis of findings on
Use of data generated outside Canada - a topic of
growing interest in oncology and pharmaceutical development
in total.

This collaboration builds on previously completed analyses and
deepens the strategic partnership in which Inka Health will strengthen its leading
Role in causal analyses and evidence transfer in the regulatory context
The results of previous work were used to
Presentation at ISPOR 2025, the leading global conference for
Health Economics, accepted.

The extension of the strategic alliance with AstraZeneca Canada confirmed
the innovative strength and reliability of Onco Innovations. Through the
continued knowledge exchange and joint market development, Onco
Innovations significantly increase its growth rate and strengthen its position as
further consolidate his position as a recognized specialist in oncology.

Here it is better to get in earlier to make bigger profits later
to be able to demonstrate.

Despite its early stage of development, the company already has
have solid funding and a team of experienced scientists,
including the renowned Prof. Steven Jones. The well-thought-out integration of
Research and therapeutic development puts Onco Innovations in the
Able to systematically overcome market-standard implementation hurdles.
A sound starting position creates ideal conditions for the development of
a major player in the global market.

The share of Onco Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ)
offers investors the extraordinary opportunity to invest in the
early stage of a potentially revolutionary technology.
Timely entry offers risk-averse investors the opportunity to benefit from the
to benefit from the first expansion cycles and to participate in the expected
to participate in disproportionate performance.

Disclaimer:

This publication is a marketing communication and forms part of a
Advertising campaign of the issuer Onco Innovations Ltd. and is aimed at
experienced and speculatively oriented investors.

This communication should not be considered as an independent financial analysis
or even investment advice, as significant conflicts of interest,
that may impair the objectivity of the creator (see
in the following section "Interests / Conflicts of Interest").

The prices given for the securities discussed are, unless
shown separately, daily closing prices of the last trading day before
respective first distribution.

Identity of the distributor and creator: MCS Market Communication Service
GmbH, registered in the commercial register of the Düsseldorf District Court under the
Number HRB 104503 and registered in the list of institute-independent
Creators and/or disseminators of investment strategies and investment recommendations
which is managed by the Federal Financial Supervisory Authority and
competent supervisory authority (hereinafter referred to as "Distributor").

Interests / Conflicts of interest

The distributor receives from the issuer for the distribution of the
Marketing communication a fixed fee. The distributor and/or
affiliated companies were informed by the issuer or their shareholders
to prepare this marketing communication. Due to the
Commissioned by the issuer, the independence of the notification
This is not guaranteed. According to the law, this justifies the distributors
or the responsible editor has a conflict of interest, which we
hereby expressly point out.

We would like to point out that the clients (third parties) of the publication of
Distributors, their bodies, major shareholders, as well as with these
affiliated parties (third parties) at the time of this publication
possibly shares of the issuer, which are included in this publication
The client and the third parties have the right to
where applicable, the intention to sell these securities in direct connection
to sell with this publication and to participate in rising prices and
to participate in sales or to purchase additional securities at any time.

The distributor therefore acts in cooperation with and on the basis of
paid contract from other persons who have significant
can hold share positions of the issuer discussed. This justifies
a conflict of interest according to law, which we hereby expressly
Neither the distributor nor the responsible editor are bound by the
involved in the possible sale/purchase activities described above.
corresponding potential share sales and purchases by the clients and
The issuer also has no influence on third parties.

The distributor must refrain from holding securities of the issuer
or to trade in any way with them. The distributor of the
Communication does not possess/hold directly or indirectly (for example
through affiliated companies, in a coordinated manner) share positions
of the issuer discussed. In addition, the remuneration of the
disseminator of the communication neither directly to financial transactions nor to
linked to stock exchange turnover or asset management fees.

Neither the distributor, nor any company affiliated with it, nor any
person involved in the creation (nor his/her closely associated
persons), nor persons who had access to the information before it was passed on
or could have, are / is in possession of a net sales or
Net long position exceeding the threshold of 0.5% of the total issued
share capital of the issuer's capital. Nor
the person(s) holds shares of more than 5% of the total issued
of the issuer’s share capital, the person(s) was/were within the
previous twelve months in the public issue of
financial instruments of the issuer, was/was the
Person(s) market maker or liquidity provider in the financial instruments of the
Issuers have an agreement with the issuer regarding the provision
of investment services as defined in Sections A and B of Annex I to
Directive 2014/65/EU, which were adopted within the previous twelve
months or during this period a service or a
A promise of performance was given under such an agreement.

Issuer: Onco Innovations Ltd.
Date of first distribution: 11.12.2024
Time of first distribution: 10:00 a.m.
Coordination with the issuer: Yes

Addressees: The distributor makes the communication available to all interested
Investment service providers and private investors at the same time
Excluded addressees: The information published by the distributor
Publications, information, analyses, reports, research and documents
are not available to US persons or persons residing in the
United States of America, Canada, Australia or Japan,
and may not be viewed by or distributed to them.
Information sources: Information sources of the distributor and
The issuer’s statements and information are based on domestic and
foreign business press, information services, news agencies
(e.g. Reuters, Bloomberg, Infront, etc.), analyses and publications
on the Internet. Standard of care: Reviews and derived
Conclusions are drawn with the care of a prudent businessman and
taking into account all information available to the public at the time
accessible factors relevant to the decision in the opinion of the author
created.

Information concerning the securities and their issuers
associated risks

Because other research houses and stock market letters can also discuss the value,
In the current recommendation period, there may be a symmetrical
Information and opinion generation.

Of course, it is important to note that the issuer is in the highest possible
Risk class for shares. The issuer may not yet have
revenues and is at early stage level, which is risky.
The company’s financial situation is still in deficit, which increases the risks
significantly increased. Any necessary capital increases could
In addition, short-term dilution effects may occur, which will be detrimental to
Investors can go. If the issuer fails to raise further
To tap into financial sources in the coming years could even lead to insolvency
and a delisting/cessation of trading is threatened.

Release from liability and risk of total loss of invested capital

The background information, market assessments and securities analyses,
which the distributor publishes on its websites and in its newsletters
published do not constitute an offer to sell the information
Quotations nor an invitation to buy or sell securities
The explanations are based on sources which the editor has provided for
trustworthy. Nevertheless, liability for financial losses that
from the use of the statements or stock discussions for the
own investment decision may result, without exception
excluded.

We would like to point out that equity investments always involve risk
Any transaction involving warrants, leveraged certificates or other
Financial products are even associated with extremely high risks.
political, economic or other changes may lead to
significant price losses, in the worst case to the total loss of the
capital invested. In the case of derivative products, the
Probability of extreme losses at least as high as
SmallCap stocks, including the large domestic and foreign stocks
You may suffer severe price losses or even total loss. You should
Before making any investment decision (e.g. through your bank or a
Get further advice from a trusted advisor.

Although the information and market assessments provided by the distributor
The evaluations and statements contained therein have been prepared with due care
We assume no responsibility or liability for errors,
omissions or false statements. This also applies to all our
The representations, figures and statements made by interviewees in the interviews
Assessments.

The entire risk arising out of the use or performance of the Service and
materials remains with you, the reader. Until
applicable law, the distributor may not
be held liable for any special, incidental
or indirect or consequential damages (including, but not
limited to loss of profit, business interruption, loss
business information or any other financial loss), which
from the use or inability to use the service and materials
use.

All statements made in this report regarding the issuer, except
historical facts, should be understood as forward-looking statements
which, due to considerable imponderables, cannot be
could come true. The statements of the author are subject
Uncertainties that should not be underestimated. There are no
Certainty or guarantee that the forecasts made will actually
Therefore, readers should not rely on the statements of the
creator and not only because of reading the message
Buy or sell securities.

The service of the distributor may therefore under no circumstances be considered as personal or
be considered as general investment advice. Users who, due to
the information displayed or ordered by the distributor
Make investment decisions or carry out transactions, trade
entirely at your own risk.

All texts, especially market assessments,
Stock assessments and chart analyses reflect the personal opinion of the
editor. These are purely individual opinions
without claiming to provide a balanced understanding of the subject matter. The reader
hereby declares that he has used all materials and contents on his own
risk and the distributor assumes no liability.

The distributor reserves the right to change the contents and materials,
which are distributed by him, without notice, to change,
improve, expand or remove. The Distributor excludes
expressly disclaims any warranty for service and materials. Service
and materials and related documentation are provided to you "as is"
is" without warranty of any kind, neither
express or implied, including, but not limited to,
implied warranties of fitness, suitability for a
specific purpose or the non-existence of an infringement.

There is no guarantee that the forecasts of the Issuer, the
creator or (other) experts and management actually
The performance of the issuer's share is therefore uncertain.
As with any so-called micro cap, there is also the risk of
Therefore, the share only serves as a dynamic addition to
an otherwise well-diversified portfolio.

The investor should follow the news closely and be informed about the
technical requirements for trading in penny stocks.
The narrow market typical of this segment ensures high volatility. Inexperienced investors
and LOW-RISK investors are advised to invest in shares of the Issuer
This analysis is directed exclusively at
to experienced professional traders.

Definitions

The decisive factor for the assessment of an issuer is whether its shares
according to the creator's assessment in the following 12 months
(validity period) better, worse or compared with the shares
comparable issuers from the same peer group:

Sell: The term Sell means to sell. The creator believes
that a further price increase is unlikely, a price loss may occur
or that investors should realize profits already made. In all
In these cases he will recommend "Sell".
Hold: The term Hold means to hold. The creator sees a
Price potential for the share, which is why he believes the share in the portfolio
to keep.
Buy: The term Buy means to purchase. The creator expects a
Increase in the share price because he currently considers it to be undervalued.
Strong Buy: The term Strong Buy means to buy without fail and is used to
Example from the US investment houses Morgan Stanley and Salomon Brothers
used. The creator expects a
above-average price increase within the same peer group.

Regardless of the assessment made, according to the
Sensitivity analysis reveals significant risks due to a change in
underlying assumptions. This discussion of risk factors in the
Analysis does not claim to be complete.


---------------------------------------------------------------------------

Issuer/Publisher: MCS Market Communication Service GmbH
Keyword(s): Finance

Publication of a press release, transmitted by EQS Group.
Media archive at https://www.eqs-news.com.

The issuer/publisher is responsible for the content of this announcement.


---------------------------------------------------------------------------

Language: German
Company: MCS Market Communication Service GmbH
Rhine Promenade 13
40789 Monheim am Rhein
 Germany
 Internet: https://www.mcsmarket.de/
EQS News ID: 2144254



End of message EQS-Media
---------------------------------------------------------------------------